NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 [Yahoo! Finance]
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on May 16, 2024 beginning at 9:00 a.m. ET in New York City. Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC , Founder and Chief Scientific Officer, BJ Jones , Chief Commercial Officer, Douglas Kling , Chief Operating Officer and Ian Somaiya , Chief Financial Officer, will be joined by renowned cardiovascular disease specialists to discuss obicetrapib's clinical development path, NewAmsterdam's commercial readiness and strategy, and the cardiovascular disease landscape and opportunities for innovative new products. Renowned cardiovascular disease specialists will include: Jorge Plutzky, M.D. , D
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma (NASDAQ: NAMS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsGlobeNewswire
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
NAMS
Sec Filings
- 5/9/24 - Form ARS
- 5/9/24 - Form DEF
- 5/9/24 - Form 8-K
- NAMS's page on the SEC website